Managing Patients With Type 2 Diabetes and Cardiorenal-Metabolic Syndrome

Mark Molitch, MD; Adrian F. Hernandez, MD


December 21, 2022

Common comorbidities associated with type 2 diabetes (T2D) include heart failure and chronic kidney disease. Each condition can aggravate the other. Over the past 5-10 years, there has been practice-changing evidence indicating that new glucose-lowering drugs, such as SGLT2 inhibitors and GLP-1 antagonists, can prevent cardiovascular events and progression of kidney disease in patients with T2D.

Endocrinologist Dr Mark Molitch, of Northwestern University, is joined by cardiovascular specialist Adrian Hernandez, from Duke University, to discuss optimal guideline-directed medical therapy for patients with T2D and cardiorenal-metabolic syndrome. They emphasize the importance of early intervention and appropriate therapeutic management.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.